In a study involving temporarily induced insulin resistance through treatment of non-esterified fatty acid (NEFA), metformin improved extrahepatic glucose utilization in patients with T2DM potentially by promoting microvascular perfusion [50, 51]
A new class of weight-loss medications, originally developed for diabetes, is now surging in popularity as obesity treatments
This helps reduce hunger and increase feelings of fullness, even with less food
For most people, gastroparesis symptoms improve after reducing the medication dose or stopping it entirely
Weight loss medications work by improving insulin sensitivity and mimicking hormones that signal fullness, making it easier to manage hunger and reduce caloric intake
It sits outside the standard benefit, so it will not help a client reach their out-of-pocket maximum faster